We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
+12.48%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$3.63B
AUM Growth
-$655M
(-15%)
Cap. Flow
-$1.05B
Cap. Flow
% of AUM
-29.05%
Top 10 Holdings %
Top 10 Hldgs %
31.08%
Holding
113
New
24
Increased
24
Reduced
34
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$90.1M |
| 2 |
AerCap
AER
|
+$80M |
| 3 |
Pfizer
PFE
|
+$73.2M |
| 4 |
Illumina
ILMN
|
+$56.4M |
| 5 |
Equifax
EFX
|
+$54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$262M |
| 2 |
Vulcan Materials
VMC
|
+$208M |
| 3 |
Bausch Health
BHC
|
+$108M |
| 4 |
AGN
Allergan Inc
AGN
|
+$107M |
| 5 |
AGN
Allergan plc
AGN
|
+$82.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Industrials | 10.32% |
| 3 | Miscellaneous | 8.86% |
| 4 | Materials | 6.21% |
| 5 | Technology | 5.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $168M | 4.64% |
2,266,756
+541,630
| +31% | +$38.2M |
|
|
2
Vulcan Materials
VMC
$34B
| $136M | 3.75% |
1,613,033
-2,697,699
| -63% | -$208M |
|
|
3
Bausch Health
BHC
$2.45B
| $129M | 3.55% |
649,042
-611,591
| -49% | -$108M |
|
|
WBA
4
DELISTED
Walgreens Boots Alliance
WBA
| $116M | 3.2% |
1,369,479
-413,341
| -23% | -$32.9M |
|
|
MIC
5
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $105M | 2.91% |
1,281,593
-381,050
| -23% | -$29M |
|
|
HOLX
6
DELISTED
Hologic
HOLX
| $101M | 2.79% |
3,067,016
-234,800
| -7% | -$7.21M |
|
|
BRCM
7
DELISTED
BROADCOM CORP CL-A
BRCM
| $97.5M | 2.69% |
2,252,695
-109,946
| -5% | -$4.79M |
|
8
UnitedHealth
UNH
$356B
| $92.9M | 2.56% |
785,745
+89,402
| +13% | +$9.93M |
|
|
9
Jazz Pharmaceuticals
JAZZ
$16B
| $90.7M | 2.5% |
+525,003
| New | +$90.1M |
|
|
10
AerCap
AER
$22.9B
| $90.3M | 2.49% |
2,067,573
+1,897,615
| +1,117% | +$80M |
|
11
Edwards Lifesciences
EW
$51.8B
| $86M | 2.37% |
3,623,226
-339,726
| -9% | -$7.62M |
|
12
McKesson
MCK
$106B
| $82.1M | 2.26% |
362,765
-32,466
| -8% | -$7.2M |
|
|
13
Pfizer
PFE
$162B
| $79.4M | 2.19% |
2,406,148
+2,301,249
| +2,194% | +$73.2M |
|
|
14
Equifax
EFX
$20.8B
| $75.8M | 2.09% |
815,059
+608,497
| +295% | +$54M |
|
15
Palo Alto Networks
PANW
$272B
| $73.2M | 2.02% |
3,006,492
-961,056
| -24% | -$21.5M |
|
16
HCA Healthcare
HCA
$87.7B
| $71.9M | 1.98% |
955,760
-930,806
| -49% | -$66.8M |
|
17
Tenet Healthcare
THC
$21.3B
| $71.5M | 1.97% |
1,443,428
+945,702
| +190% | +$44.2M |
|
18
Humana
HUM
$48.2B
| $71M | 1.96% |
398,692
-146,973
| -27% | -$23.3M |
|
|
19
Illumina
ILMN
$33B
| $69.6M | 1.92% |
385,356
+299,360
| +348% | +$56.4M |
|
20
Stryker
SYK
$116B
| $66.2M | 1.82% |
717,374
-479,404
| -40% | -$44.6M |
|
21
Gilead Sciences
GILD
$187B
| $63.5M | 1.75% |
647,337
-444,344
| -41% | -$45.1M |
|
|
KYTH
22
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $62.3M | 1.72% |
1,242,509
+157,194
| +14% | +$6.6M |
|
23
ManpowerGroup
MAN
$2.88B
| $60.7M | 1.67% |
+704,901
| New | +$53.7M |
|
24
Blackrock
BLK
$174B
| $60.7M | 1.67% |
165,831
+48,993
| +42% | +$17.8M |
|
25
Meta Platforms (Facebook)
META
$1.57T
| $60.6M | 1.67% |
736,859
+304,139
| +70% | +$23.8M |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q1 2015 Portfolio in Review
As of Q1 2015, PFM Health Sciences held 113 positions worth $3.63B, down 15% from $4.28B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
PFM Health Sciences withdrew a net $1.05B in Q1 2015, closing 30 positions and reducing 34 holdings. Its most notable exit was Microsoft, an estimated $262M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 53% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, PFM Health Sciences opened a new position in Jazz Pharmaceuticals worth $90.7M.
- PFM Health Sciences's largest Q1 2015 buy was Jazz Pharmaceuticals: 525,003 shares worth $90.7M.
- PFM Health Sciences added most to AerCap in Q1 2015, an estimated $80M increase.
- PFM Health Sciences's biggest Q1 2015 reduction was Vulcan Materials, cutting an estimated $208M.
- PFM Health Sciences fully exited Microsoft in Q1 2015, selling an estimated $262M.
- PFM Health Sciences's ten largest holdings make up 31% of its $3.63B portfolio in Q1 2015.
- PFM Health Sciences opened 24 new positions and closed 30 in Q1 2015.
- PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $3.63B.
Based on PFM Health Sciences's 13F filing for Q1 2015, filed 15 May 2015.